Literature DB >> 10948351

Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience.

G Bacci1, P Ruggieri, F Bertoni, S Ferrari, A Longhi, R Biagini, M Zavatta, M Versari, C Forni.   

Abstract

Five-hundred and twenty-six patients with non-metastatic osteosarcoma of the extremities treated at Istituto Ortopedico Rizzoli from 1983 to 1995 with neoadjuvant chemotherapy and limb salvage, were retrospectively studied to evaluate the rate of local and systemic control. At a mean follow-up of 9.5 years (3-17), 320 patients remained continuously free of disease and 206 relapsed. The 5-year disease-free survival and overall survival were 64% and 70% respectively. In patients who relapsed, there were 31 local recurrences (6%). The rate of local failures was significantly higher in the 79 patients with inadequate surgical margins (marginal, intralesional, and contaminated margins) than in the 486 patients with wide surgical margins (2.6% vs. 25.0%; P<0.0001). Twenty-nine of the 31 patients (94%) with local recurrence also had metastases and died of the tumor. In comparison with patients who only had a systemic relapse, patients with local recurrences had a higher rate of metastases located in bones (41% vs. 7%; P<0.001), and a worse post-relapse outcome (5-year overall survival: 6% vs. 24%; P<0.04). We concluded that in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: i) limb salvages procedures do not compromise the outcome of patients, provided the achievement of adequate surgical margins; ii) local recurrences are a marker either of the inadequacy of local treatment or of the high local and systemic aggressiveness of the tumor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948351     DOI: 10.3892/or.7.5.1129

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Research: Is resection of tumours involving the pelvic ring justified? : A review of 49 consecutive cases.

Authors:  Alex Yuen; Eugene T Ek; Peter Fm Choong
Journal:  Int Semin Surg Oncol       Date:  2005-04-09

2.  Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: a retrospective study.

Authors:  Guangke Yuan; Jingming Chen; Dongjin Wu; Chunzheng Gao
Journal:  Onco Targets Ther       Date:  2017-05-26       Impact factor: 4.147

3.  BMP-2 and miR-29c in osteosarcoma tissues on proliferation and invasion of osteosarcoma cells.

Authors:  Xueqing Chen; Yingjian Zhang
Journal:  Oncol Lett       Date:  2019-04-08       Impact factor: 2.967

4.  Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Sana Mohiuddin; Dhruva K Mishra; Min P Kim; Joseph A Ludwig; Sandhya Krishnan; Alejandra Ruiz Velasco; Amelia M Vetter; Kristi Pence; David McCall; Danh D Truong; Branko Cuglievan; Brian A Menegaz; Budi Utama; Najat C Daw; Eric R Molina; Rafal J Zielinski; John A Livingston; Richard Gorlick; Antonios G Mikos
Journal:  Cancer Gene Ther       Date:  2021-01-06       Impact factor: 5.987

5.  The impact of miR-9 in osteosarcoma: A study based on meta-analysis, TCGA data, and bioinformatics analysis.

Authors:  Fengfeng Wu; Xuesheng Jiang; Qun Wang; Qian Lu; Fengxiang He; Jianyou Li; Xiongfeng Li; Mingchao Jin; Juntao Xu
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.